Identification of alternative splicing-derived cancer neoantigens for mRNA vaccine development

Area of Science:

• Oncology
• Immunology
• Bioinformatics

Background:

• Messenger RNA (mRNA) vaccines show significant promise for cancer therapy due to their safety, efficacy, and production advantages.
• Identifying suitable cancer neoantigens for mRNA vaccine targeting remains a critical challenge in oncology.
• Tumor-specific proteins arising from abnormal alternative splicing present a potential source for novel neoantigens.

Purpose of the Study:

• To address the challenge of identifying alternative splicing-derived cancer neoantigens for mRNA vaccine development.
• To summarize the difficulties and challenges associated with identifying these neoantigens from RNA-sequencing data.
• To propose a framework for designing personalized mRNA vaccines utilizing alternative splicing neoantigens.

Main Methods:

• Leveraging high-throughput technologies for systematic characterization of alternative splicing events in tumors.
• Analyzing RNA-sequencing data to identify tumor-specific transcripts and resultant proteins.
• Developing a conceptual framework for personalized mRNA vaccine design based on identified neoantigens.

Main Results:

• Alternative splicing generates tumor-specific proteins that can serve as neoantigens.
• RNA-sequencing data analysis is crucial for identifying these splicing-derived neoantigens.
• A conceptual framework for personalized mRNA vaccine design has been proposed.

Conclusions:

• Alternative splicing is a viable source for identifying cancer neoantigens for mRNA vaccine development.
• Overcoming challenges in neoantigen identification from RNA-seq data is key.
• Personalized mRNA vaccines based on alternative splicing neoantigens hold significant therapeutic potential.